{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T18:01:14Z","timestamp":1780596074930,"version":"3.54.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.clinre.2018.08.013","type":"journal-article","created":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T18:04:38Z","timestamp":1537898678000},"page":"236-243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Recent developments in the research on biomarkers of cholangiocarcinoma in primary sclerosing cholangitis"],"prefix":"10.1016","volume":"43","author":[{"given":"Andreas","family":"Wannhoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel N.","family":"Gotthardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clinre.2018.08.013_bib0005","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.23294","article-title":"Diagnosis and management of primary sclerosing cholangitis","volume":"51","author":"Chapman","year":"2010","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.clinre.2018.08.013_bib0010","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0168-8278(01)00288-4","article-title":"Hepatic and extra-hepatic malignancies in primary sclerosing cholangitis","volume":"36","author":"Bergquist","year":"2002","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2018.08.013_bib0015","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jhep.2008.08.013","article-title":"High lifetime risk of cancer in primary sclerosing cholangitis","volume":"50","author":"Claessen","year":"2009","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.clinre.2018.08.013_bib0020","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1002\/hep.24570","article-title":"Cancer surveillance in patients with primary sclerosing cholangitis","volume":"54","author":"Razumilava","year":"2011","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.clinre.2018.08.013_bib0025","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1055\/s-2006-933562","article-title":"Primary sclerosing cholangitis and cholangiocarcinoma","volume":"26","author":"Lazaridis","year":"2006","journal-title":"Semin Liver Dis"},{"issue":"11","key":"10.1016\/j.clinre.2018.08.013_bib0030","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1007\/s10620-006-9681-4","article-title":"Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis","volume":"52","author":"Fevery","year":"2007","journal-title":"Dig Dis Sci"},{"issue":"6","key":"10.1016\/j.clinre.2018.08.013_bib0035","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/hep.26565","article-title":"Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis","volume":"58","author":"Boonstra","year":"2013","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.clinre.2018.08.013_bib0040","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/hep.29730","article-title":"Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis","volume":"67","author":"Ali","year":"2018","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.clinre.2018.08.013_bib0045","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/ajg.2015.112","article-title":"American college of. ACG clinical guideline: primary sclerosing cholangitis","volume":"110","author":"Lindor","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.clinre.2018.08.013_bib0050","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jhep.2013.08.005","article-title":"FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis","volume":"59","author":"Wannhoff","year":"2013","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.clinre.2018.08.013_bib0055","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.pan.2016.09.013","article-title":"Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping","volume":"16","author":"Luo","year":"2016","journal-title":"Pancreatology"},{"issue":"3","key":"10.1016\/j.clinre.2018.08.013_bib0060","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.pan.2017.04.006","article-title":"Comment re: \u201cOptimize CA 19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping\u201d","volume":"17","author":"Wannhoff","year":"2017","journal-title":"Pancreatology"},{"issue":"9","key":"10.1016\/j.clinre.2018.08.013_bib0065","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1007\/s10620-005-2927-8","article-title":"The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis","volume":"50","author":"Levy","year":"2005","journal-title":"Dig Dis Sci"},{"issue":"5","key":"10.1016\/j.clinre.2018.08.013_bib0070","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.cgh.2011.02.007","article-title":"Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma","volume":"9","author":"Sinakos","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.clinre.2018.08.013_bib0075","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1007\/s10620-012-2401-3","article-title":"Increased serum levels of carbohydrate antigen 19-9 and outcomes in primary sclerosing cholangitis patients without cholangiocarcinoma","volume":"58","author":"Venkatesh","year":"2013","journal-title":"Dig Dis Sci"},{"issue":"13","key":"10.1016\/j.clinre.2018.08.013_bib0080","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.cgh.2015.07.014","article-title":"Inflammation but not biliary obstruction is associated with carbohydrate antigen 19-9 levels in patients with primary sclerosing cholangitis","volume":"13","author":"Wannhoff","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2018.08.013_bib0085","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1177\/2050640615581577","article-title":"A common genetic variant of fucosyltransferase 2 correlates with serum carcinoembryonic antigen levels and affects cancer screening in patients with primary sclerosing cholangitis","volume":"4","author":"Wannhoff","year":"2016","journal-title":"United Eur Gastroenterol J"},{"issue":"2","key":"10.1016\/j.clinre.2018.08.013_bib0090","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s10620-016-4370-4","article-title":"Carcinoembryonic antigen level in primary sclerosing cholangitis is not influenced by dominant strictures or bacterial cholangitis","volume":"62","author":"Wannhoff","year":"2017","journal-title":"Dig Dis Sci"},{"issue":"1","key":"10.1016\/j.clinre.2018.08.013_bib0095","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/gutjnl-2012-303434","article-title":"A genome-wide association study of genetic loci that influence tumour biomarkers cancer antigen 19-9, carcinoembryonic antigen and alpha fetoprotein and their associations with cancer risk","volume":"63","author":"He","year":"2014","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.clinre.2018.08.013_bib0100","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/cncy.21331","article-title":"Primary sclerosing cholangitis with equivocal cytology: fluorescence in situ hybridization and serum CA 19-9 predict risk of malignancy","volume":"121","author":"Barr Fritcher","year":"2013","journal-title":"Cancer Cytopathol"},{"issue":"1","key":"10.1016\/j.clinre.2018.08.013_bib0105","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0973-6883(11)60110-2","article-title":"Circulating CYFRA 21-1 is a specific diagnostic and prognostic biomarker in biliary tract cancer","volume":"1","author":"Chapman","year":"2011","journal-title":"J Clin Exp Hepatol"},{"issue":"5","key":"10.1016\/j.clinre.2018.08.013_bib0110","doi-asserted-by":"crossref","first-page":"e97046","DOI":"10.1371\/journal.pone.0097046","article-title":"Angiopoietin-2 and biliary diseases: elevated serum, but not bile levels are associated with cholangiocarcinoma","volume":"9","author":"Voigtlander","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.clinre.2018.08.013_bib0115","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.dld.2014.06.010","article-title":"The impact of elevated serum IgG4 levels in patients with primary sclerosing cholangitis","volume":"46","author":"Benito de Valle","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.clinre.2018.08.013_bib0120","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/prca.201600141","article-title":"Identification of fucosylated Fetuin-A as a potential biomarker for cholangiocarcinoma","volume":"11","author":"Betesh","year":"2017","journal-title":"Proteomics Clin Appl"},{"issue":"1","key":"10.1016\/j.clinre.2018.08.013_bib0125","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/cei.12776","article-title":"Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma","volume":"185","author":"Bernuzzi","year":"2016","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1016\/j.clinre.2018.08.013_bib0130","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/gutjnl-2016-311739","article-title":"Anti-GP2 IgA autoanti-bodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis","volume":"66","author":"Jendrek","year":"2017","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.clinre.2018.08.013_bib0135","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jhep.2012.10.013","article-title":"Improvement of serum alkaline phosphatase to\u2009<\u20091.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis","volume":"58","author":"Al Mamari","year":"2013","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.clinre.2018.08.013_bib0140","first-page":"246","article-title":"Alkaline phosphatase normalization is a biomarker of improved survival in primary sclerosing cholangitis","volume":"15","author":"Hilscher","year":"2016","journal-title":"Ann Hepatol"},{"issue":"7","key":"10.1016\/j.clinre.2018.08.013_bib0145","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.cgh.2012.12.032","article-title":"Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis","volume":"11","author":"Lindstrom","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11\u201312","key":"10.1016\/j.clinre.2018.08.013_bib0150","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/apt.12979","article-title":"Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis","volume":"40","author":"Rupp","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.clinre.2018.08.013_bib0155","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.dld.2010.12.008","article-title":"Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis","volume":"43","author":"Stanich","year":"2011","journal-title":"Dig Liver Dis"},{"issue":"5","key":"10.1016\/j.clinre.2018.08.013_bib0160","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/MCG.0000000000000502","article-title":"Elevated serum bilirubin level correlates with the development of cholangiocarcinoma, subsequent liver transplantation, and death in patients with primary sclerosing cholangitis","volume":"50","author":"Haseeb","year":"2016","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"10.1016\/j.clinre.2018.08.013_bib0165","first-page":"1","article-title":"Greater biosynthetic liver dysfunction in primary sclerosing cholangitis suggests co-existent or impending cholangiocarcinoma","volume":"4","author":"Trilianos","year":"2016","journal-title":"J Clin Transl Hepatol"},{"issue":"8","key":"10.1016\/j.clinre.2018.08.013_bib0170","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1053\/j.gastro.2017.02.038","article-title":"Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis","volume":"152","author":"Weismuller","year":"2017","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.clinre.2018.08.013_bib0175","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/2050640617717156","article-title":"Impact of age at diagnosis on disease progression in patients with primary sclerosing cholangitis","volume":"6","author":"Rupp","year":"2018","journal-title":"United Eur Gastroenterol J"},{"issue":"10","key":"10.1016\/j.clinre.2018.08.013_bib0180","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1097\/MCG.0000000000000042","article-title":"Calprotectin in bile: a disease severity marker in patients with primary sclerosing cholangitis","volume":"48","author":"Voigtlander","year":"2014","journal-title":"J Clin Gastroenterol"},{"issue":"10","key":"10.1016\/j.clinre.2018.08.013_bib0185","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3109\/00365521.2013.825313","article-title":"Anti-neutrophil cytoplasmic antibodies in bile are associated with disease activity in primary sclerosing cholangitis","volume":"48","author":"Lenzen","year":"2013","journal-title":"Scand J Gastroenterol"},{"issue":"3","key":"10.1016\/j.clinre.2018.08.013_bib0190","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/hep.27050","article-title":"Human bile contains microRNA-laden extra-cellular vesicles that can be used for cholangiocarcinoma diagnosis","volume":"60","author":"Li","year":"2014","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.clinre.2018.08.013_bib0195","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1007\/s10620-014-3034-5","article-title":"Analysis of U2 small nuclear RNA fragments in the bile differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders","volume":"59","author":"Baraniskin","year":"2014","journal-title":"Dig Dis Sci"},{"issue":"6","key":"10.1016\/j.clinre.2018.08.013_bib0200","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1477-2574.2011.00296.x","article-title":"Differences in phosphatidylcholine and bile acids in bile from Egyptian and UK patients with and without cholangiocarcinoma","volume":"13","author":"Hashim Abdalla","year":"2011","journal-title":"HPB (Oxford)"},{"issue":"8","key":"10.1016\/j.clinre.2018.08.013_bib0205","doi-asserted-by":"crossref","first-page":"e0182924","DOI":"10.1371\/journal.pone.0182924","article-title":"Bile microbiota in primary sclerosing cholangitis: impact on disease progression and development of biliary dysplasia","volume":"12","author":"Pereira","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.clinre.2018.08.013_bib0210","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1186\/s12879-014-0562-8","article-title":"Risk factors and outcome in patients with primary sclerosing cholangitis with persistent biliary candidiasis","volume":"14","author":"Rupp","year":"2014","journal-title":"BMC Infect Dis"},{"issue":"3","key":"10.1016\/j.clinre.2018.08.013_bib0215","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/hep.24103","article-title":"Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis","volume":"53","author":"Lankisch","year":"2011","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.clinre.2018.08.013_bib0220","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/gutjnl-2012-302047","article-title":"Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders","volume":"62","author":"Metzger","year":"2013","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.clinre.2018.08.013_bib0225","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1177\/2050640616687836","article-title":"A combined bile and urine proteomic test for cholangiocarcinoma diagnosis in patients with biliary strictures of unknown origin","volume":"5","author":"Voigtlander","year":"2017","journal-title":"United Eur Gastroenterol J"},{"issue":"2","key":"10.1016\/j.clinre.2018.08.013_bib0230","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1093\/gastro\/gou066","article-title":"Bile proteomics for differentiation of malignant from benign biliary strictures: a pilot study","volume":"3","author":"Navaneethan","year":"2015","journal-title":"Gastroenterol Rep (Oxf)"},{"issue":"6","key":"10.1016\/j.clinre.2018.08.013_bib0235","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/ajg.2014.60","article-title":"Lipidomic profiling of bile in distinguishing benign from malignant biliary strictures: a single-blinded pilot study","volume":"109","author":"Navaneethan","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.clinre.2018.08.013_bib0240","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.gie.2014.09.041","article-title":"Volatile organic compounds in bile for early diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis: a pilot study","volume":"81","author":"Navaneethan","year":"2015","journal-title":"Gastrointest Endosc"},{"issue":"7","key":"10.1016\/j.clinre.2018.08.013_bib0245","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1007\/s10620-015-3596-x","article-title":"Volatile organic compounds in urine for non-invasive diagnosis of malignant biliary strictures: a pilot study","volume":"60","author":"Navaneethan","year":"2015","journal-title":"Dig Dis Sci"},{"issue":"6","key":"10.1016\/j.clinre.2018.08.013_bib0250","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1477-2574.2010.00185.x","article-title":"Metabolic profiling of bile in cholangiocarcinoma using in vitro magnetic resonance spectroscopy","volume":"12","author":"Sharif","year":"2010","journal-title":"HPB (Oxford)"},{"issue":"4 Pt B","key":"10.1016\/j.clinre.2018.08.013_bib0255","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.bbadis.2017.09.012","article-title":"Pathological features of primary sclerosing cholangitis identified by bile proteomic analysis","volume":"1864","author":"Rupp","year":"2018","journal-title":"Biochim Biophys Acta"},{"issue":"10","key":"10.1016\/j.clinre.2018.08.013_bib0260","doi-asserted-by":"crossref","first-page":"e0139305","DOI":"10.1371\/journal.pone.0139305","article-title":"MicroRNAs in serum and bile of patients with primary sclerosing cholangitis and\/or cholangiocarcinoma","volume":"10","author":"Voigtlander","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.clinre.2018.08.013_bib0265","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/hep.29291","article-title":"Serum extra-cellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma","volume":"66","author":"Arbelaiz","year":"2017","journal-title":"Hepatology"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740118301773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740118301773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:28:09Z","timestamp":1761895689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740118301773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S2210740118301773"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2018.08.013","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent developments in the research on biomarkers of cholangiocarcinoma in primary sclerosing cholangitis","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2018.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}